New Data Demonstrate Benefits of Aranesp(R) Dosed Every Two Weeks in European Haemodialysis Patients With CKD-Related Anaemia

Studies Show Patients Switched to Every-Two-Week Dosing With
Aranesp Achieve Stable Haemoglobin Levels and
Receive Fewer Injections

Amgen (Nasdaq:AMGN), the world's largest biotechnology company,
today announced new trial results from two studies,(1)(2) showing that
Aranesp(R) (darbepoetin alfa) administered every two weeks (Q2W) is an
effective treatment for chronic kidney disease (CKD) anaemia patients
in European dialysis settings. The data were presented today at the
2006 European Renal Association - European Dialysis and Transplant
Association Congress (ERA-EDTA). One of these studies formed the basis
for a European Medicines Agency (EMEA) Aranesp label update in Europe
earlier this year. This label update offers the benefit of switching
to Aranesp Q2W from any recombinant human erythropoietin (rHuEPO)
dosing regimen without requiring a dose increase.
"For patients with anaemia associated with chronic kidney disease,
achieving stable haemoglobin levels within the target range as
recommended by the European Best Practice Guidelines is an important
goal," said Fernando Carrera, MD, Eurodial Dialysis Clinic, Leiria,
Portugal. "The results presented today are good news for patients and
physicians as the Aranesp every two week dosing regimen means this
goal can be achieved with less frequent injections. This can help to
improve operational efficiency in dialysis centres."
The results showed the Aranesp Q2W was as effective as Aranesp
once weekly (QW) or other rHuEPO QW in maintaining haemoglobin (Hb)
stability in the normal range (Hb 10-13 g/dL), with no evidence of
overshooting Hb target or increased risk of adverse events.(1)
"Aranesp is the only erythropoietin stimulating agent available in
Europe that offers the treatment option of every two week IV dosing
for all haemodialysis patients," said William Sheridan, MD, vice
president, medical affairs, Amgen International.
"Amgen remains committed to improving the lives of chronic kidney
disease patients and is delighted that the EMEA has recognised the
importance of this new data and labelling to offer a new option to the
Aranesp dosing regimen."
With nearly two million patients treated with Aranesp worldwide,
Amgen continues its commitment to improving the lives of patients with
CKD through meaningful offerings, such as label updates and an
extensive Phase 3 clinical trials programme to study the effect of
treating anaemia or CKD complications in different patient
populations. At ERA-EDTA today, Amgen also announced EVOLVE
(EValuation Of Cinacalcet HCI Therapy to Lower CardioVascular
Events)(TM), the first international, prospective clinical outcomes
study designed to determine whether treating secondary
hyperparathyroidism (HPT) with Mimpara (cinacalcet HCl) can
effectively reduce the risk of mortality and cardiovascular morbidity
in patients undergoing maintenance dialysis. Amgen recently announced
the initiation of the large-scale Phase 3 RED-HF (Reduction of Events
with Darbepoetin alfa in Heart Failure) Trial(TM) that will evaluate
the effect of treatment of anaemia with Aranesp on morbidity and
mortality in patients with symptomatic heart failure. Amgen continues
its ongoing TREAT (Trial to Reduce cardiovascular Events and Aranesp
Therapy) trial in diabetic patients with CKD and anaemia not requiring
dialysis.

About the Phase 3 Data Presented at ERA-EDTA

This 30-week Phase 3 multicentre, double-blind study of 308
haemodialysis patients compared the safety and efficacy of Aranesp Q2W
and QW following a switch from rHuEPO. (2) Patients treated with
rHuEPO were randomised to switch to either Aranesp Q2W or Aranesp QW
for 24 weeks, and Hb and dose were reassessed during weeks 25-30.
Results showed that Aranesp Q2W and QW were comparable in maintaining
Hb with no dose increase after switching from rHuEPO. Additionally,
Aranesp Q2W was not associated with an increased frequency of Hb
greater than 14 g/dL, a level associated with vascular risk, nor was
there a difference in the incidence of vascular disorders or
cerebrovascular accidents between the two arms.
The investigators concluded that Aranesp Q2W keeps haemodialysis
patients within their target range, with no evidence of an increase of
overshooting Hb target or increased risk of adverse vascular events.

Additional Aranesp Data Presented at ERA-EDTA

In another study, 105 haemodialysis patients (41 percent female,
mean age 64.4 years) were followed for 12 months.(1) During the first
six months, they received Aranesp QW, and were switched to receive
Aranesp Q2W for the second six months. The investigators found that
switching dose regimen resulted in no significant differences in mean
haemoglobin levels (P = 0.8) or in mean weekly dose of Aranesp (P =
0.3). They concluded that a switch from Aranesp QW or Q2W maintained
efficacy in stabilising Hb levels without the need for increased
dosing.

About CKD and Anaemia

According to recently published research, around ten percent of
Europeans suffer from CKD,(3) an irreversible condition characterised
by kidney damage and impaired function that often progresses over
time. Patients with CKD often suffer from serious complications such
as anaemia, which occurs when failing kidneys no longer produce
sufficient erythropoietin, a hormone that stimulates the production of
oxygen-carrying red blood cells (RBCs). RBCs contain Hb, a red,
iron-rich protein that carries oxygen from the lungs to all of the
body's tissues. Oxygen provides the energy the body needs for normal
activities. Anaemia occurs when the number of RBCs (or the Hb in them)
falls below normal. Anaemia is defined by the World Health
Organisation (WHO) and European Best Practice Guidelines (EBPG) as
Hb less than 12 g/dL in women and Hb less than 13 g/dL in men.

About Aranesp(R) (darbepoetin alfa)

Aranesp is a recombinant erythropoietic protein (a protein that
stimulates production of red blood cells, which carry oxygen). Amgen
revolutionised the treatment of anaemia with the development of
recombinant erythropoietin, Epoetin alfa. Building on this heritage,
Amgen developed Aranesp, a unique erythropoiesis stimulating protein,
which contains two additional sialic acid-containing carbohydrate
chains compared to the epoetin alfa molecule and remains in the
bloodstream longer than epoetin alfa as demonstrated by its longer
half-life.(4)
Aranesp was granted marketing authorisation by the European
Commission in 2001 for the treatment of anaemia associated with
chronic renal failure in adults and paediatric subjects 11 years of
age or older. Approval was granted in 2004 for an extended dosing of
up to once monthly for the treatment of anaemia in CKD patients not on
dialysis. In 2006, the Aranesp label was updated to allow CKD patients
on dialysis to switch from rHuEPO one to three times a week to Aranesp
every two weeks.
Aranesp is contraindicated in patients with uncontrolled
hypertension. Erythropoietic therapies may increase the risk of
thrombotic events and other serious events.(5) The target haemoglobin
should not exceed 14 g/dL. If the Hb increase exceeds 2.5 g/dL in any
four-week period, dose reductions are recommended.
Pure red cell aplasia (PRCA) caused by neutralising
anti-erythropoietin antibodies has been reported in association with
erythropoietin therapy. These antibodies have been shown to
cross-react with all erythropoietic proteins, and patients suspected
or confirmed to have neutralising antibodies to erythropoietin should
not be switched to Aranesp.
The most commonly reported side effects in clinical trials were
headache, hypertension, injection site pain and thrombosis of vascular
access.(6)

About Amgen

Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realise the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics has changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives.

Forward-Looking Statement

This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below
and others that can be found in Amgen's Form 10-K for the year ended
December 31, 2005, and in Amgen's periodic reports on Form 10-Q and
Form 8-K. Amgen is providing this information as of the date of this
news release and does not undertake any obligation to update any
forward-looking statements contained in this document as a result of
new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe
and effective performance of product candidates in humans. The
complexity of the human body cannot be perfectly, or sometimes, even
adequately modeled by computer or cell culture systems or animal
models. The length of time that it takes for us to complete clinical
trials and obtain regulatory approval for product marketing has in the
past varied and we expect similar variability in the future. We
develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates
that are derived from relationships may be subject to disputes between
the parties or may prove to be not as effective or as safe as we may
have believed at the time of entering into such relationship. Also, we
or others could identify side effects or manufacturing problems with
our products after they are on the market. In addition, sales of our
products are affected by the availability of reimbursement and the
reimbursement policies imposed by third party payors, including
governments, private insurance plans and managed care providers, and
may be affected by domestic and international trends toward managed
care and healthcare cost containment as well as possible U.S.
legislation affecting pharmaceutical pricing and reimbursement.
Government regulations and reimbursement policies may affect the
development, usage and pricing of our products. In addition, we
compete with other companies with respect to some of our marketed
products as well as for the discovery and development of new products.
We believe that some of our newer products, product candidates or new
indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against
products that have lower prices, established reimbursement, superior
performance, are easier to administer, or that are otherwise
competitive with our products. In addition, while we routinely obtain
patents for our products and technology, the protection offered by our
patents and patent applications may be challenged, invalidated or
circumvented by our competitors and there can be no guarantee of our
ability to obtain or maintain patent protection for our products or
product candidates. We cannot guarantee that it will be able to
produce commercially successful products or maintain the commercial
success of our existing products.
Our stock price may be affected by actual or perceived market
opportunity, competitive position, and success or failure of our
products or product candidates. Further, the discovery of significant
problems with a product similar to one of our products that implicate
an entire class of products could have a material adverse effect on
sales of the affected products and on our business and results of
operations. The scientific information discussed in this news release
related to our product candidates is preliminary and investigative.
Such product candidates are not approved by the U.S. Food and Drug
Administration (FDA), and no conclusions can or should be drawn
regarding the safety or effectiveness of the product candidates. Only
the FDA can determine whether the product candidates are safe and
effective for the use(s) being investigated. Further, the scientific
information discussed in this news release relating to new indications
for our products is preliminary and investigative and is not part of
the labelling approved by the FDA for the products. The products are
not approved for the investigational use(s) discussed in this news
release, and no conclusions can or should be drawn regarding the
safety or effectiveness of the products for these uses. Only the FDA
can determine whether the products are safe and effective for these
uses. Healthcare professionals should refer to and rely upon the
FDA-approved labelling for the products, and not the information
discussed in this news release.
-0-
*T
(1)Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C. Aranesp
(darbepoetin alfa) administered once every two weeks (Q2W)
maintains recommended haemoglobin (Hb) in chronic kidney disease
(CKD) patients on haemodialysis switched from weekly (QW) dosing.
Abstract presented at XLIII European Renal Association's European
Dialysis and Transfusion Association Congress (ERA-EDTA). 15-18
July 2006; Glasgow, UK.

(2)Locatelli F, Backs W, Del Pino MD, et al. Control of anemia with
Aranesp(R): Hb stability achieved with fewer patients requiring
dose adjustments after switching to Aranesp(R) every two weeks.
Abstract presented at XLIII European Renal Association's European
Dialysis and Transfusion Association Congress (ERA-EDTA) congress.
15-18 July 2006; Glasgow, UK.

(3)De Zeeuw D, Hillege HL, de Jong PE. The kidney, a cardiovascular
risk marker, and a new target for therapy. Kidney Int Suppl 2005;
98: S25-S29.

(4)Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel
erythropoiesis stimulating protein compared with epoetin alfa in
dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395.

(5)Aranesp summary of product information

(6)Aranesp Prescribing Information;
http://www.aranesp.com/pdf/aranesp_PI.pdf.
Last accessed: 27 June 2006.
*T